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The TNFSF13B (TNF superfamily member 13b) gene encodes BAFF, a cytokine with a
crucial role in the differentiation and activation of B cells. An insertion-deletion variant
(GCTGT!A) of this gene, leading to increased levels of BAFF, has been recently implicated
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in the genetic predisposition to several autoimmune diseases, including multiple sclerosis,
systemic lupus erythematosus, and rheumatoid arthritis. Based on the elevated levels of
this cytokine found in patients with giant cell arteritis (GCA) and systemic sclerosis (SSc),
we aimed to assess whether this functional variant also represents a novel genetic risk fac-
tor for these two disorders.
Methods
A total of 1,728 biopsy-proven GCA patients from 4 European cohorts, 4,584 SSc patients
from 3 European cohorts and 5,160 ethnically-matched healthy controls were included in
the study. The single nucleotide polymorphism (SNP) rs374039502, which colocalizes with
the genetic variant previously implicated in autoimmunity, was genotyped using a custom
TaqMan assay. First, association analysis was conducted in each independent cohort using
χ2 test in Plink (v1.9). Subsequently, different case/control sets were meta-analyzed by the
inverse variance method.
Results
No statistically significant differences were found when allele distributions were compared
between cases and controls for any of the analyzed cohorts. Similarly, combined analysis of
the different sets evidenced a lack of association of the rs374039502 variant with GCA (P =
0.421; OR (95% CI) = 0.92 (0.75–1.13)) and SSc (P = 0.500; OR (95% CI) = 1.05 (0.91–
1.22)). The stratified analysis considering the main clinical subphenotypes of these diseases
yielded similar negative results.
Conclusion
Our data suggest that the TNFSF13B functional variant does not contribute to the genetic
network underlying GCA and SSc.
Introduction
Autoimmune diseases are complex disorders caused for the combined effect of both environ-
mental and polygenic risk factors. In recent years, genetic studies have identified hundreds of
loci implicated in the susceptibility of immune-mediated conditions, many of which are shared
by different diseases, thus highlighting the existence of shared pathogenic mechanisms in auto-
immunity [1].
In this regard, a genetic variant of the TNFSF13B (TNF superfamily member 13b) gene has
been recently involved in the susceptibility to several autoimmune disorders, including multi-
ple sclerosis (MS), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE) [2].
TNFSF13B encodes BAFF (B-cell activating factor), a cytokine belonging to the tumor necrosis
factor (TNF) ligand family with a key role in the differentiation and activation of B cells [3].
The TNFSF13B autoimmune-associated variant is an insertion-deletion (GCTGT!A) that
creates a shorter 30 UTR transcript lacking a miRNA binding site. This leads to higher levels of
soluble BAFF, which results in an increased number of B cells and a reduction of the circulat-
ing monocytes [2]. Interestingly, recent studies have described increased levels of BAFF in
giant cell arteritis (GCA) [4, 5] and systemic sclerosis (SSc) patients [6]. Specifically, in GCA,
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serum BAFF levels appeared to be positively correlated with disease activity and inversely cor-
related with circulating B cell number [4, 5]. Regarding SSc, it has been demonstrated that
patients showing IFN type I signature had higher monocyte BAFF mRNA levels [7]. In addi-
tion, BAFF has also been implicated in the production of both IgG and IL6 by B cells [8] and
collagen by dermal fibroblasts in SSc patients [9], thus contributing to the inflammatory and
fibrotic processes occurring in this disorder.
Taking this into account, we decided to investigate for first time the possible implication of
the TNFSF13B functional variant in GCA and SSc by analyzing the largest cohorts of patients
with these two diseases so far.
Materials and methods
Study population
A total of 1,728 biopsy-proven GCA patients, 4,584 SSc patients, and 5,160 ethnically-matched
healthy controls, all of them of European origin, were included in the study. Additional infor-
mation about the case/control sets included in the analysis is provided in Table 1.
Approval from the Comite´ de Bioe´tica del Consejo Superior de Investigaciones Cientı´ficas
and the local ethical committees of the different participating centers (Hospital Vall d’Hebron,
Hospital Clinic, Hospital Universitario de Bellvitge, Hospital del Mar, Hospital General de
Granollers, Hospital de la Santa Creu i Sant Pau, Hospital Universitari Arnau de Vilanova,
Consorci Corporacio´ Sanitària Parc Taulı´ de Sabadell, Hospital Universitario Mu´tuaTerrassa,
Hospital Universitario A Coruña, Hosptal Xeral-Calde, Complejo Hospitalario Universitario
de Vigo, Hospital A´lvaro Cunqueiro, Hospital Carlos Haya, Hospital Virgen de la Victoria,
Hospital Regional de Ma´laga, Hospital Reina Sofı´a, Hospital Clı´nico Universitario San Cecilio,
Hospital Vı´rgen de las Nieves, Hospital Vı´rgen del Rocı´o, Hospital 12 de octubre, Hospital
Clı´nico San Carlos, Hospital Gregorio Maraño´n, Hospital La Paz, Hospital La Princesa, Hospi-
tal Ramo´n y Cajal, Hospital Universitario HM Sanchinarro, Hospital Puerta de Hierro, Hospi-
tal de Cruces, Hospital Universitario de Galdakao, Hospital Virgen del Camino, Hospital
Central de Asturias, Hospital Marque´s de Valdecilla, Hospital Universitario Doctor Peset,
Hospital La Fe´, Hospital Clı´nico Universitario Lozano Blesa, Hospital Universitario Miguel
Servet, Hospital de Son Llàtzer, Hospital Universitario de Canarias, ASST Degli Spedali Civili
Di Brescia, Fondazione IRCCS Ca’ Granda Ospedale Maggioire Policlinico di Milano, Univer-
sità degli Studi di Verona, Ospedale Torrette di Ancona, Azienda Ospedaliera ASMN, Univer-
sity Hospital of Parma, University of Genova, Catholic University of Sacred Heart, Ospedali
Riuniti, Università Vita-Salute San Raffaele, University of Firenze, Robert-Bosch-Hospital,
Hannover Medical School, University of Luebeck, University of Jena, Leeds Teaching
Table 1. Case/control sets included in the present study.
GCA SSc Controls










Spain 891 63.0 83.62 ± 8.71 2,086 89.5 61.76 ± 15.10b 3,200 68.1 45.15 ± 11.75
Italy 326 80.2 79.04 ± 7.09b 1,105 90.6 58.64 ± 15.53 1,118 44.8b 51.12 ± 14.53b
Germany 186 78.9 67.53 ± 8.84 - - - 470 56.0b 55.32 ± 6.96
UK 325 69.2 72.90 ± 7.36 1,393 85.2 63.97 ± 14.39b 372 44.5 43.57 ± 8.23b
Total 1,728 4,584 5,160
a Age at the sample collection
b Data available for less than 60% of individuals.
https://doi.org/10.1371/journal.pone.0209343.t001
TNFSF13B variant in systemic sclerosis and giant cell arteritis
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Hospitals NHS Trust, Southend University Hospital NHS Foundation Trust, Ipswich Hospital
NHS Trust, King’s College London, University of Glasgow, Newcastle University, Royal Free
and University College Medical School, University of Manchester) and informed written con-
sent from all participants were obtained in accordance with the tenets of the Declaration of
Helsinki.
GCA patients had a positive temporal artery biopsy (disruption of the internal elastic lami-
nae with infiltration of mononuclear cells into the arterial wall with or without multinucleated
giant cells) and fulfilled the 1990 American College of Rheumatology (ACR) classification cri-
teria [10]. SSc patients fulfilled the 1980 ACR preliminary classification criteria for the disease
[11] or exhibited at least 3 of 5 features of CREST syndrome (calcinosis, Raynaud’s phenome-
non, esophageal dysmotility, sclerodactyly, telangiectasias).
Patients with GCA were stratified according to the presence/absence of the main clinical
phenotypes of the disease, polymyalgia rheumatica, jaw claudication, and visual manifestations
(transient visual loss including amaurosis fugax, permanent visual loss, or diplopia). SSc
patients were stratified according to the extent of skin involvement and autoantibody status as
limited cutaneous SSc (lcSSc), diffuse cutaneous SSc (dcSSc), positive for anticentromere anti-
bodies (ACA), and positive for antitopoisomerase antibodies (ATA).
Genotyping methods
Genomic DNA was extracted from peripheral white blood cells using standard procedures. All
individuals were genotyped for the single nucleotide polymorphism (SNP) rs374039502
(1099T>A), which colocalizes with the insertion/deletion variant previously implicated in
autoimmunity, using a TaqMan allelic discrimination custom assay (ID: AH0JGPG) with the
following primers: forward 5’-GACAGCATCCCGGTTTTCATTTTAT-3’ and reverse 5’-TG
TAAACTGTTAAATGAAGTAAACAGTTAAAACTGA-3’. Genotyping was performed in a
7900HT Fast Real-time polymerase chain reaction system (Applied Biosystems, Foster City,
CA, USA).
Statistical analysis
The overall statistical power of the analysis was calculated using CaTS (http://www.sph.umich.
edu/csg/abecasis/CaTS/). Hardy–Weinberg equilibrium (HWE) was tested at a significance
level of 0.05. The statistical analysis to compare allelic distributions was carried out using χ2
test in Plink (v1.9) (https://www.cog-genomics.org/plink2). Then, results from the different
cohorts were combined using inverse variance weighted meta-analysis under a fixed-effects
model. Heterogeneity of the ORs across cohorts was assessed using Cochran’s Q test. Odds
ratios (OR) and 95% confidence intervals (CI) were obtained according to Woolf’s method. P-
values<0.05 were considered statistically significant.
Results
Genotyping success rate was higher than 95%. Genotypic frequencies did not deviate from
HWE.
Results of the association analysis of each individual case/control set and the combined
analysis are shown in Tables 2 and 3. First, allele frequencies were compared between cases
and controls for each independent cohort. Regarding GCA, a trend for association was
observed in the German population (186 cases and 470 controls; p = 0.069); however, no sig-
nificant association was found for any of the remaining case/control sets, despite of the higher
sample size and allele frequency of both the Spanish (891 cases and 3,200 controls) and Italian
(326 cases and 1,118 controls) cohorts (Table 2).
TNFSF13B variant in systemic sclerosis and giant cell arteritis
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On the other hand, no association of this polymorphism with SSc was observed in any of
the three analyzed cohorts (Table 3).
Accordingly, when the different case/control sets were combined in a meta-analysis, a lack
of association of the TNFSF13B variant with both diseases, GCA (P = 0.421, OR = 0.92) and
SSc (P = 0.936, OR = 1.00), was evident (Tables 2 and 3).
Subsequently, to examine whether this polymorphism might affect specific clinical subgroups,
GCA and SSc patients were stratified according to the main clinical manifestations of each disease.
Again, the subphenotype analysis yielded similar negative results in each case/control set (data not
shown) as well as in the meta-analysis of the different cohorts (S1 and S2 Tables).
Discussion
Different lines of evidence suggest that BAFF plays a relevant role in the pathogenic process
occurring in autoimmune disorders. Interestingly, Belimumab, a monoclonal antibody against
BAFF, was recently approved for SLE treatment and is currently undergoing Phase III clinical
trial in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Genetic studies
also support the role of this cytokine in SLE, MS and RA. In this regard, a TNFSF13B
Table 2. Association analysis of the TNFSF13B rs374039502 variant in four independent GCA cohorts and meta-analysis.
Genotype, N (%) Allele test
Cohort Subgroup (N) TT TA AA MAF P-value OR [95% CI] �
Spain Controls (n = 3,200) 10 (0.31) 249 (7.78) 2941 (91.91) 4.20 0.170 0.82 [0.62–1.09]
GCA (n = 891) 0 (0) 62 (6.96) 829 (93.04) 3.48
Italy Controls (n = 1,118) 3 (0.27) 125 (11.18) 990 (88.55) 5.86 0.533 0.88 [0.59–1.30]
GCA (n = 326) 0 (0) 34 (10.43) 292 (89.57) 5.21
Germany Controls (n = 470) 0 (0) 19 (4.04) 451 (95.96) 2.02 0.069 1.89 [0.94–3.82]
GCA (n = 186) 0 (0) 14 (7.53) 172 (92.47) 3.76
UK Controls (n = 372) 0 (0) 17 (4.57) 355 (95.43) 2.28 0.977 1.01 [0.50–2.00]
GCA (n = 325) 0 (0) 15 (4.62) 310 (95.38) 2.31
Overall meta-analysis Controls (n = 5,160) 0.421 0.92 [0.75–1.13]
GCA (n = 1,728)
GCA, giant cell arteritis; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
� OR for the minor allele (A).
https://doi.org/10.1371/journal.pone.0209343.t002
Table 3. Association analysis of the TNFSF13B rs374039502 variant in three independent SSc cohorts and meta-analysis.
Genotype, N (%) Allele test
Cohort Subgroup (N) TT TA AA MAF P-value OR [95% CI]�
Spain Controls (n = 3,200) 10 (0.31) 249 (7.78) 2941 (91.91) 4.20 0.326 1.10 [0.91–1.33]
SSc (n = 2,086) 5 (0.24) 182 (8.72) 1899 (91.04) 4.60
Italy Controls (n = 1,118) 3 (0.27) 125 (11.18) 990 (88.55) 5.86 0.822 0.97 [0.75–1.25]
SSc (n = 1,105) 5 (0.45) 116 (10.50) 984 (89.05) 5.70
UK Controls (n = 372) 0 (0) 17 (4.57) 355 (95.43) 2.28 0.893 1.04 [0.60–1.78]
SSc (n = 1,393) 1 (0.07) 64 (4.59) 1328 (95.33) 2.37
Overall meta-analysis Controls (n = 4,690) 0.500 1.05 [0.91–1.22]
SSc (n = 4,584)
SSc, systemic sclerosis; MAF, minor allele frequency; OR, odds ratio; CI, confidence interval.
� OR for the minor allele (A).
https://doi.org/10.1371/journal.pone.0209343.t003
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insertion-deletion variant, which leads to higher levels of BAFF, has been proposed as a com-
mon genetic risk factor in autoimmunity. Elevated levels of BAFF have been found in GCA
and SSc patients, thus providing a strong rationale for the study of the TNFSF13B functional
variant in the genetic predisposition to these disorders.
Large-scale genetic analyses have already been performed in both GCA [12] and SSc [13];
however, since the genotyping platforms used in this kind of studies only include SNPs and
small indels, the potential role of other type of genetic variants, which could help to clarify part
of the missing heritability of these conditions, remains unexplored. Taking this into account,
we decided to investigate the possible implication of the TNFSF13B functional variant in the
GCA and SSc pathogenesis through a candidate gene approach. However, our data evidenced
a lack of association of this genetic variant with both disorders.
Despite the low prevalence of SSc and the low frequency of the analyzed polymorphism,
our study had enough statistical power to detect a similar effect to that reported for other auto-
immune diseases (~ 80% to detect ORs previously described for MS (1.27), RA (1.24), or SLE
(1.44)), therefore, it is unlikely that the lack of association observed herein was due to a type II
error. With respect to GCA, although our study had enough statistical power to detect moder-
ate effects (80% to detect an OR�1.36), a weaker effect of this variant in GCA can not be
completely discarded. Nevertheless, according to the results of the meta-analysis of the differ-
ent GCA cohorts, the minor allele (A) was found to have an opposite effect in this condition
(OR = 0.92) compared to that previously described for other diseases. Therefore, it is unlikely
that replication studies including larger sample sets result in a different outcome.
Although our data indicated that the TNFSF13B deletion is not involved in GCA and SSc,
an implication of other polymorphisms within this locus, in low linkage disequilibrium with
the variant analyzed here, can not be ruled out. However, it should be noted that no signals
within this region were detected in previous large-scale genetic analyses. Another possibility is
that genetic variants located in regulatory regions some distant apart of the TNFSF13B gene
are influencing its expression.
In conclusion, in the present study we have failed to identify an association between the
TNFSF13B functional variant previously associated with autoimmunity and two immune-
related diseases, GCA and SSc. Thus, this genetic variant does not seem to be responsible for
the increased levels of BAFF found in these disorders.
Supporting information
S1 Table. Results of the meta-analysis of the different GCA cohorts after stratification of
patients according to their main clinical characteristics. OR, odds ratio. PMR, polymyalgia
rheumatica; JC, jaw claudication; VM, visual manifestations; OR, odds ratio. aOR for the
minor allele.
(PDF)
S2 Table. Results of the meta-analysis of the different SSc cohorts after stratification of
patients according to their main clinical characteristics. lSSc, limited cutaneous SSc; dSSc,
diffuse cutaneous SSc; ACA, anticentromere antibodies; ATA, antitopoisomerase antibodies
OR, odds ratio. aOR for the minor allele.
(PDF)
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